Die elektrochemische Fluorierung von Alkansulfonamiden und Alkandisulfonamiden
作者:P. Satori、C. Jünger
DOI:10.1016/0022-1139(96)03478-1
日期:1996.7
Alkane sulphonylamides and disulphonylamides are stable in anhydrous (HF)x and undergo quantitative fission of S-N bonds during electrochemical fluorination. Besides NF3, the corresponding perfluoroalkane sulphonyl fluorides and disulphonyl fluorides are formed.
[EN] PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE À ACTIVITÉ PESTICIDE
申请人:SYNGENTA PARTICIPATIONS AG
公开号:WO2018234240A1
公开(公告)日:2018-12-27
Compounds of formula (I), as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.
Carbon-chain isomerization during the electrochemical fluorination in anhydrous hydrogen fluoride—a mechanistic study
作者:Nikolai V. Ignat’ev、Urs Welz-Biermann、Udo Heider、Andriy Kucheryna、Stefan von Ahsen、Wolfgang Habel、Peter Sartori、Helge Willner
DOI:10.1016/s0022-1139(03)00174-x
日期:2003.11
i-C3H7SO2F and cyclo-C3H7C(O)F have been subjected to electrochemical fluorination in anhydrous hydrogenfluoride. The resulting products were fully analyzed by NMR spectroscopy. From the reaction balances, literature data and quantum chemical calculations, a new mechanism for carbon-chain isomerization during the electrochemical fluorination (ECF) is proposed. The key step in the formation of isomeric products
化合物i -C 4 H 9 SO 2 F,i -C 3 H 7 SO 2 F和环-C 3 H 7 C(O)F已在无水氟化氢中进行了电化学氟化。通过NMR光谱对所得产物进行全面分析。从反应平衡,文献数据和量子化学计算出发,提出了一种在电化学氟化过程中碳链异构化的新机理。据信形成异构体产物的关键步骤是涉及碳阳离子或双自由基中间体的闭环反应。
PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS
申请人:Shekhar Shashank
公开号:US20130224149A1
公开(公告)日:2013-08-29
This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.
This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.